Physician profile
Amy E Parry
NPI 1336121664
$7,719.45
in general payments reported to CMS, 2019-2025
49 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $1,161 · 2021: $1,766 · 2022: $1,190 · 2023: $549 · 2024: $831 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.06 |
| Education | $133.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,146.46 | 2020-2025 | |
| Lilly USA, LLC | $931.95 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $718.71 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $434.11 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $423.50 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $388.56 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $326.46 | 2020-2021 | |
| Mylan Specialty L.P. | $304.91 | 2019-2024 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $296.41 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $293.22 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.77 | 2019-2025 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $201.22 | 2020-2025 | Zoryve, Livalo, Seglentis |
| Takeda Pharmaceuticals U.S.A., INC. | $200.34 | 2019-2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company Ltd. | $193.66 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.59 | 2019-2024 | Spiriva Respimat |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Parry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.